Establishment Labs Holdings Inc. (NASDAQ:ESTA) Shares Purchased by Barclays PLC

Barclays PLC grew its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 9,643.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,471 shares of the company's stock after buying an additional 31,148 shares during the period. Barclays PLC owned 0.11% of Establishment Labs worth $1,362,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ESTA. Hood River Capital Management LLC acquired a new position in shares of Establishment Labs in the 2nd quarter valued at $43,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Establishment Labs in the 3rd quarter valued at $127,000. Nkcfo LLC acquired a new position in shares of Establishment Labs in the 2nd quarter valued at $227,000. Black Swift Group LLC acquired a new position in shares of Establishment Labs in the 3rd quarter valued at $312,000. Finally, Verition Fund Management LLC boosted its holdings in shares of Establishment Labs by 22.8% in the 3rd quarter. Verition Fund Management LLC now owns 9,400 shares of the company's stock valued at $407,000 after buying an additional 1,746 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company's stock.

Wall Street Analyst Weigh In

ESTA has been the subject of several research reports. BTIG Research upped their price target on shares of Establishment Labs from $62.00 to $65.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Stephens upgraded shares of Establishment Labs to a "strong-buy" rating in a research report on Monday, December 2nd. Finally, Citigroup upped their price target on shares of Establishment Labs from $45.00 to $50.00 and gave the company a "neutral" rating in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $60.60.

Establishment Labs Stock Performance

Establishment Labs stock traded down $12.08 during trading hours on Monday, reaching $33.71. 4,041,162 shares of the stock were exchanged, compared to its average volume of 999,245. The stock has a market cap of $943.81 million, a P/E ratio of -13.07 and a beta of 1.15. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. Establishment Labs Holdings Inc. has a 52-week low of $30.20 and a 52-week high of $60.12. The firm's 50 day moving average is $44.31 and its 200 day moving average is $43.75.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.